TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 27.88

Change

0.00 (0.00)%

Market Cap

USD 1.03B

Volume

0.62M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.76 (+0.39%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-1.77 (-0.17%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-1.54 (-0.57%)

USD 34.86B
ARGX argenx NV ADR

-13.04 (-2.40%)

USD 32.89B
MRNA Moderna Inc

-0.87 (-1.42%)

USD 25.27B
BGNE BeiGene Ltd

+12.40 (+5.31%)

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

+5.86 (+1.67%)

USD 15.95B
SMMT Summit Therapeutics PLC

+0.48 (+2.58%)

USD 15.35B
PCVX Vaxcyte Inc

+0.21 (+0.19%)

USD 14.00B

ETFs Containing TARS

SLX VanEck Steel ETF 4.95 % 0.56 %

+0.54 (+0.96%)

N/A
BASE:CA Evolve Global Materials &.. 4.91 % 0.00 %

+0.09 (+0.96%)

CAD 0.05B
FXZ First Trust Materials Alp.. 4.66 % 0.64 %

+0.63 (+0.96%)

N/A
XME SPDR® S&P Metals and Min.. 4.65 % 0.35 %

+0.82 (+0.96%)

N/A
SMLL Harbor ETF Trust 3.53 % 0.28 %

+0.23 (+0.96%)

N/A
XMHQ Invesco S&P MidCap Qualit.. 2.22 % 0.25 %

+0.81 (+0.96%)

USD 5.69B
PICK 1.52 % 0.39 %

N/A

N/A
IVOG Vanguard S&P Mid-Cap 400 .. 1.13 % 0.20 %

+1.02 (+0.96%)

USD 1.08B
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.03 % 0.15 %

+0.73 (+0.96%)

N/A
QVMM Invesco Exchange-Traded F.. 0.64 % 0.00 %

+0.27 (+0.96%)

USD 0.32B
ZMID:CA BMO S&P US Mid Cap Index .. 0.63 % 0.00 %

+0.42 (+0.96%)

N/A
MDY SPDR® S&P MIDCAP 400 ETF.. 0.58 % 0.24 %

+5.29 (+0.96%)

USD 22.75B
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.58 % 0.00 %

+0.95 (+0.96%)

USD 2.36B
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.58 % 0.00 %

+1.37 (+0.96%)

N/A
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.58 % 0.00 %

+1.05 (+0.96%)

USD 1.99B
IVOO Vanguard S&P Mid-Cap 400 .. 0.58 % 0.15 %

+0.97 (+0.96%)

USD 2.25B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+0.27 (+0.96%)

N/A
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

+0.82 (+0.96%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.68% 83% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.68% 83% B 89% A-
Trailing 12 Months  
Capital Gain 58.32% 88% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.32% 88% B+ 92% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.71% 62% D 56% F
Dividend Return 3.71% 62% D 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.32% 55% F 33% F
Risk Adjusted Return 7.22% 66% D+ 46% F
Market Capitalization 1.03B 82% B 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector